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ABSTRACT
The mammalian target of rapamycin complex 1 (mTORC1) complex is the major nutrient sensor in mammalian cells that responds to
amino acids, energy levels, growth factors, and hormones, such as insulin, to control anabolic and catabolic processes. We have
recently shown that suppression of themTORC1 complex in bone-forming osteoblasts (OBs) improved glucose handling inmalemice
fed a normal or obesogenic diet. Mechanistically, this occurs, at least in part, by increasing OB insulin sensitivity leading to upregula-
tion of glucose uptake and glycolysis. Given previously reported sex-dependent differences observed upon antagonism of mTORC1
signaling, we investigated themetabolic and skeletal effects of genetic inactivation of preosteoblastic-mTORC1 in femalemice. Eight-
week-old control diet (CD)-fed Rptorob
−/− mice had a low bone mass with a significant reduction in trabecular bone volume and tra-
becular number, reduced cortical bone thickness, and increased marrow adiposity. Despite no changes in body composition, CD-fed
Rptorob
−/− mice exhibited significant lower fasting insulin and glucose levels and increased insulin sensitivity. Upon high-fat diet
(HFD) feeding, Rptorob
−/− mice were resistant to a diet-induced increase in whole-body and total fat mass and protected from the
development of diet-induced insulin resistance. Notably, although 12 weeks of HFD increased marrow adiposity, with minimal
changes in both trabecular and cortical bone in the female control mice, marrow adiposity was significantly reduced in HFD-fed
Rptorob
−/− compared to both HFD-fed control and CD-fed Rptorob
−/− mice. Collectively, our results demonstrate that mTORC1 func-
tion in preosteoblasts is crucial for skeletal development and skeletal regulation of glucose homeostasis in both male and female
mice. Importantly, loss of mTORC1 function in OBs results in metabolic and physiological adaptations that mirror a caloric restriction
phenotype (under CD) and protects against HFD-induced obesity, associated insulin resistance, and marrow adiposity expansion.
These results highlight the critical contribution of the skeleton in the regulation of whole-body energy homeostasis. © 2021 The
Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
KEY WORDS: BONE MARROW ADIPOSE TISSUE; DIET-INDUCED INSULIN RESISTANCE; DIET-INDUCED OBESITY; mTORC1; PREOSTEOBLAST
Introduction
Dysregulated insulin signaling and the development of insu-lin insensitivity are common features of many chronic
disorders including obesity, diabetes, and heart disease.(1) Fur-
thermore, excessive nutrient consumption, or overnutrition, is a
major contributing factor to the increasing prevalence of these
metabolic diseases in humans.(2) At the center of cellular
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responses to nutritional challenges is the mammalian target of
rapamycin complex 1 (mTORC1) complex, the primary-nutrient-
sensing hub that responds to changes in intracellular nutrient
status to promote cellular growth and anabolic metabolism.
Binding of insulin to its receptor (INSR) indirectly activates
mTORC1, which in turn promotes messenger RNA (mRNA) trans-
lation, ribosome biogenesis, and lipid synthesis, among other
processes.(3) mTORC1 negatively regulates insulin signaling by
disrupting the interaction between INSR and its adaptor protein,
IRS1, via (i) activation of ribosomal protein S6 kinase (S6K1),
which phosphorylates IRS1 at Ser270/307/1101 and thus induces ubi-
quitin-mediated proteasomal degradation of IRS1(4–6); (ii) activation
and stabilization of the receptor growth factor receptor-bound pro-
tein 10 (Grb10), which inhibits IRS1 from binding to activated
INSR(7,8); and/or (iii) direct phosphorylation of IRS1 at Ser636/639, sites
that lie in close proximity to the phosphatidylinositol-30 kinase (PI3K)
activation motif, the phosphorylation of which suppresses activa-
tion of PI3K downstream of IRS1.(9)
In addition to insulin, multiple nutrient signals independently
stimulate the mTORC1 pathway (reviewed in Ali et al.(10)). These
include amino acids, in particular the branched chain amino acid
leucine (BCAAs), via Ras-related small GTP binding protein (RAG)
guanosine triphosphatase (GTPase)-dependent signaling.(11)
mTORC1 activity is also stimulated by glucose and fatty acids
through cellular energy status. Under conditions of low cellular
energy levels (high adenosine monophosphate [AMP]/adeno-
sine triphosphate [ATP] ratio) the AMP-dependent kinase
(AMPK) represses mTORC1 signaling through phosphorylation
of the tuberous sclerosis 1/2 (TSC1/2) complex, a negative regu-
lator of mTORC1(12) and RAPTOR.(13) Consequently, in states of
nutrient overload, mTORC1 is chronically activated, leading to
sustained stimulation of S6K1 and S6K1-mediated phosphoryla-
tion and degradation of IRS1.(14) This desensitizes cellular insulin
signaling and impairs the PI3K/protein kinase B (AKT) signaling
pathway, thus rendering cells resistant to insulin.(15) Thus, as a
consequence of chronically high nutrient levels, mTORC1
remains active and maintains the negative feedback loop to
the INSR, leading to systemic insulin insensitivity.(16)
Inhibition of mTORC1 or elements of the mTORC1 signaling
pathway, either genetically or pharmacologically, is associated
with an improved metabolic profile. For example, treatment with
rapamycin, an mTORC1 inhibitor, dose-dependently increased life-
span in both male and female mice.(17) However, when relative
life-extension was compared, the effects were consistently greater
in the females thanmales.(18) Furthermore, whole-body inactivation
of S6K1, a downstream target of mTORC1, protects against diet-
induced insulin resistance and obesity, due to elevated lipolysis
and metabolic rate, in male mice only,(19) but extends lifespan in
female mice.(20) Consistent with this, increased expression of
eukaryotic translation initiation factor 4E binding protein 1 (4E-
BP1), whose inhibitory effect on mRNA translation is countered by
mTORC1, protects against both aging-induced and high-fat diet
(HFD)-induced obesity and metabolic impairments only in male
mice,(21) whereas combined disruption of 4E-BP1 and 4E-BP2 has
the opposite effect, with these mice displaying increased adiposity
and sensitivity to both HFD-induced obesity and insulin resis-
tance.(22) Collectively, these results suggest that the beneficial
effects of reduced mTORC1 signaling is sex-dependent.
The skeleton has recently emerged as a critical insulin target
tissue. Importantly, insulin signaling in osteoblasts (OBs), is nec-
essary for whole-body glucose homeostasis, whereby OB-
specific deletion of INSR (INSROB−/−) causes elevated blood glu-
cose, increased insulin resistance, and increased peripheral fat
mass in animals fed a normal diet,(23,24) while overexpression or
downregulation of INSR in OBs results in profound changes in
systemic glucose metabolism in response to an obesogenic
diet.(25,26) Consistent with these observations, we recently
showed that suppression of the mTORC1 complex in pre-OB
improved glucose handling in male mice fed a normal or HFD,
at least in part, through an increase in OB insulin sensitivity lead-
ing to upregulation of glucose uptake and glycolysis.(27) Given
the sexually dimorphic effects observed upon reduced mTORC1
signaling in other studies, we investigated the effects of genetic
inactivation of preosteoblastic mTORC1 (OB-mTORC1) in
female mice.
Materials and Methods
Transgenic mice and diet
All mice were bred and group-housed (maximum 5 mice/cage)
in pathogen-free conditions at the South Australian Health and
Medical Research Institute (SAHMRI) Bioresources Facility
(Adelaide, SA, Australia) under a 12-hour light–dark cycle (lights
on at 7:00 a.m.) at constant temperature (20–23C), with ad libi-
tum access to a standard chow diet (Teklad Global Diet #2918:
18.6% protein, 6.2% fat; Envigo, Indianapolis, IN, USA) and water.
For diet-induced obesity studies, mice were fed an HFD (Spe-
cialty Feeds #SF16-096: 19.4% protein, 23% fat [43.4% of total
energy from fat]; Specialty Feeds, Perth, Australia) from weaning
to 16 weeks of age. All studies were performed with institutional
ethics approval (SAHMRI Animal Ethics Committee, #SAM164).
Female conditional knockout mice, in which Rptorwas disrupted
in early osteoprogenitor cells, were generated using Osx1-GFP::
Cre mice,(28) R26eYFP mice,(29) and Rptorfl/fl mice(30) as
described.(31) Wild-type littermates were used as controls as
detailed in our previous study.(27) Animals were weighed twice-
weekly and at the end of the study, body length and whole-body
lean and fat mass were measured postmortem using a dedicated
mouse dual X-ray absorptiometer (Lunar Piximus II; GE Medical
Systems, Madison, WI, USA) or EchoMRI Body Composition Anal-
ysis (EchoMRI LLC, Houston, TX, USA).
Metabolic phenotyping
Insulin and glucose tolerance tests (ITT and GTT, respectively)
and indirect calorimetry assessment were performed as
described.(27)
High-resolution micro–computed tomography scanning
X-ray micro–computed tomography (μCT) was performed using
a SkyScan 1176 (Bruker, Kontich, Belgium). Tibias were scanned
at 55 kV/455 mA using a 0.5-mm aluminum filter, a 0.6 rotation
step, and three-frame averaging with an isometric resolution of
8.78 μm/pixel. Three-dimensional reconstruction of the scan
data (smoothing, 1, ring artifact, 8, and beam hardening, 30%)
was performed using NRecon (Bruker). Analysis of the bone
microarchitecture was performed using CTAn (Bruker). Cortical
bone measurements were calculated as the average of measure-
ments in the lateral, medial, caudal, and cranial orientation from
three slices of cortical bone. Analysis and nomenclature of μCT
follow recommended standard.(32) Specifically, slices were
selected in relation to the primary spongiosa. For analysis of
the proximal tibia, a trabecular region of interest was manually
defined to exclude the cortex. For trabecular bone, the region
of analysis was determined as an area of 150 microtomographic
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slices, commencing 35 slices distal to the primary spongiosa of a
13-mm tibia. Images were reconstructed and threshold values
established using a specimen-specific threshold. To ensure that
the analysis of trabecular bone was conducted in corresponding
regions of the secondary spongiosa proximal to the growth
plate, the distance from the primary spongiosa and the area ana-
lyzed was normalized to the length of the tibia. Tibial length
measurements were performed using CTAn software (Bruker)
and taken from the proximal tibial head to the fibular notch.
Enzyme-linked immunosorbent assay
Fasted blood samples were collected via cardiac puncture into
Minicollect tubes (Greiner Bio One, Kremsmünster, Austria) as
described.(27) Commercial enzyme-linked immunosorbent assay
(ELISA) kits were used for the measurement of: insulin (EZRMI-
13K; Millipore, Burlington, MA, USA), leptin (EZML-82K; Millipore),
adiponectin (EZMADP-60K; Millipore), osteocalcin [OCN] (BT-470;
Alfa Aesar, Lancashire, UK), and undercarboxylated OCN
(unOCN) (MK129; TaKaRa Bio, Otsu, Japan) per the manufac-
turer’s instructions.
Histology
Tibias were fixed in 10% formalin and decalcified in 0.5M ethyle-
nediaminetetraacetic acid (EDTA) pH 8.0 solution before being
processed and embedded into paraffin wax. Sections (5 μm)
were stained with hematoxylin and eosin, and images were
taken using a NanoZoomer 2.0 (Hamamatsu Photonics, Hama-
matsu City, Japan). The region of interest for the proximal mouse
tibias was defined as a region of secondary spongiosa distal from
the primary spongiosa to a distance of 1.8 mm. The percentage
adipocyte area per marrow area (Ad.Ar/Ma.Ar), adipocyte area
per number of adipocytes (Ad.Ar/Ad.N), and number of adipo-
cytes per marrow area (N.AdC/Ma.Ar) were quantified using
Osteomeasure software (OsteoMetrics, Decatur, GA, USA). Bone
histomorphometry nomenclature follows recommended
standards.(33)
Protein isolation and Western blotting
Protein isolationfromtissuesamples,Westernblotting,andquantita-
tive analysis were performed as described.(27) Antibodies for immu-
noblotting are phospho-rpS6Ser240/244 (CST2215S), phosphor-
AKTSer473 (CST4060), ACTIN (A5441), and UCP1 (ab209483).
RNA isolation and quantitative reverse-transcription
polymerase chain reaction
RNA isolation of tissue samples and quantitative reverse-
transcriptionpolymerasechain reaction (RT-PCR)wereperformed
as described.(27) The following forward and reverse primer pairs
were used for real-time PCR: Actin, 50-TTGCTGACACGATG-
CAGGA-30 and 50-AAGGGTGTAAAACGCAGCTC-30; Pcg-1α, 50-
TGTGTGCTGTGTGTCAGAGT-30 and 50-ACCAGAGCAGCACACTC-
TATG-30, and Ucp1, 50-TGGTGAACCCGACAACTTCC-30 and
50- GGCCTTCACCTTGGATCTGAA-30.
Statistical analysis
All data are presented as presented as box-plots with mean,
maximum, andminimum values. All data were plotted. Statistical
analyses were performed using a one-way or two-way analysis of
variance (ANOVA) with a Tukey’s post hoc test or an unpaired
Student’s t test using GraphPad Prism (GraphPad Software, Inc.,
La Jolla, CA, USA). Significance was accepted at p < 0.05, with
asterisks denoting p value levels: *p < 0.05; **p < 0.01;
***p < 0.001 unless stated otherwise.
Results
Loss of mTORC1 function in pre-OBs reduced bone mass
but increased systemic insulin sensitivity in female mice
In previous studies, we have investigated the function of
mTORC1 in skeletal development, osteoblast-mediated B cell
development, and skeletal control of glucose homeostasis using
male mice with conditional deletion of Rptor, an essential com-
ponent of mTORC1, in pre-OBs (Rptorob
−/− mice).(27,31,34) In our
most recent study, we showed that suppression of the mTORC1
complex in OBs improved glucose handling in male mice fed a
control diet (CD) or high-fat diet (HFD), at least in part, by increas-
ing OB insulin sensitivity leading to upregulation of glucose
uptake and glycolysis.(27) To determine if this important observa-
tion was sex-dependent, female Rptorob
−/− mice were fed a CD
and assessments of bone phenotype and glucose metabolism
were examined.
As shown in Figure 1A and B, 8-week-old female Rptorob
−/−
mice weighed significantly less and were approximately 10%
shorter in length than the controls. However, although total fat
mass was significantly lower in female Rptorob
−/− mice
(Figure 1C), correcting fat mass to account for the differences
in total body weight (as a percentage of total body weight:
Figure 1D) or body length (fat mass index [FMI]: fat mass/height2,
Figure 1E) showed that the reduction in fat mass in the females
was proportional to their lower body mass. Consistent with this,
no significant differences in body weight–adjusted fat depots
were observed in female Rptorob
−/− mice relative to controls
(Figure 1F). Conversely, bone mineral density (BMD; g/cm2) mea-
sured by whole-body dual-energy X-ray absorptiometry (DXA)
scan, was significantly reduced in the female Rptorob
−/− mice
(Figure 1G). Furthermore, analysis of trabecular bone, using
μCT, revealed a significant reduction in bone volume (BV/TV)
and trabecular number (Tb.N) in the female Rptorob
−/−mice com-
pared to controls, whereas both trabecular thickness (Tb.Th) and
separation (Tb.Sp) were unchanged (Figure 1H–K). Cortical thick-
ness (Ct.Th) was also significantly reduced in the tibial diaphysis
of female Rptorob
−/− mice (Figure 1L). Consistent with their low
bone mass, circulating levels of both total and undercarboxy-
lated osteocalcin were significantly reduced in the Rptorob
−/−
mice (Figure 1M,N). Interestingly, despite no change in their per-
centage of whole-body adiposity, female Rptorob
−/− mice
showed improved whole-body insulin sensitivity, as measured
by an ITT, which was associated with elevated circulating adipo-
nectin levels (Figure 1O,P). Moreover, female Rptorob
−/− mice
have significantly lower fasting glucose and insulin levels
(Figure 1Q,R). Conversely, no significant change in glucose toler-
ance was observed in female Rptorob
−/− mice (Figure 1S).
Suppression of OB-mTORC1 protects female mice from
diet-induced insulin resistance
A previous study byWei et al.(25) showed that bones fromwild-type
mice that have been challengedwith a HFD exhibit features of insu-
lin resistance such as reduced insulin-stimulated phosphorylation
of AKT at Ser473 and downregulation of the INSR. This reduction in
OB insulin signaling was also observed in other primary insulin
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target tissues such as liver, skeletal muscle, and adipose tissues.(25)
To investigate if insulin resistance in bone is associated with hyper-
activation of mTORC1, we fed wild-type mice an obesogenic HFD
for 12 weeks (from 4 to 16 weeks of age) and measured the basal
phosphorylation levels of ribosomal S6 (rpS6 Ser240/244), a substrate
for p70S6K, a primary mTORC1 effector,(35) as a readout of mTORC1
activity. As a control, we measured basal levels of AKT P-Ser473,
which has previously been shown to be increased in liver and
Fig. 1. Loss of OB-mTORC1 function in 8-week-old female mice results in low bone mass but increased peripheral insulin sensitivity. (A) Body weight
(n = 15/genotype). (B) Body length, as measured from nose to anus (n = 5/genotype). (C) DXA analysis of fat mass and (D) % fat mass normalized to total
body weight (n = 5/genotype). (E) FMI (n = 5/genotype). (F) Body weight-adjusted iWAT and gWAT mass (n = 10/genotype). (G) Whole-body BMD, mea-
sured by DXA (n = 5/genotype). (H–L) Quantitative assessment of the trabecular bone of the tibia measured by high-resolution μCT: BV, TV, Tb.N, Tb.Th, Tb.
Sp, Ct.Th (n = 6/genotype). (M) Serum levels of total OCN (n = 6–13/genotype). (N) Serum levels of unOCN (n = 6–10/genotype). (O) Insulin tolerance test
and area under the curve analysis at 8 weeks of age (n = 11–13/genotype). (P) Serum adiponectin levels (n = 6–10/genotype). (Q) Fasting blood glucose
levels (n = 11–13/genotype). (R) Fasting serum insulin levels (n = 9–13/genotype). (S) Glucose tolerance test and incremental area under the curve analysis
(n = 11–13/genotype). In all panels, data are presented as box-plot with mean, maximum, and minimum values. *p < 0.05, **p < 0.01, ***p < 0.001,
Student t test. Abbreviations: μCT, micro–computed tomography; BMD, bonemineral density; BV, bone volume; Ct.Th, cortical thickness; DXA, dual-energy
absorptiometry; FMI, fat mass index; gWAT, gonadal white adipose tissue; iWAT, inguinal white adipose tissue; mTORC1, mammalian target of rapamycin
complex 1; OB, osteoblast; OCN, osteocalcin; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; TV, total volume; unOCN,
undercarboxylated OCN.
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muscle in response to HFD feeding.(36–38) Consistentwith these pre-
vious studies, basal levels of AKT P-Ser473 were also elevated in
bone (Figure 2A). Moreover, basal levels of rpS6 P-Ser240/244 were
higher in bone after HFD feeding, compared to CD, suggesting that
hyperactivation of mTORC1 could be involved in the development
of bone-specific insulin resistance.
To determine if suppression of OB-mTORC1 under HFD feed-
ing could protect animals from developing diet-induced glucose
intolerance and insulin resistance, age-matched female control
and Rptorob
−/− mice were fed a CD or an obesogenic HFD for
12 weeks and changes to metabolic parameters were assessed.
Fasting glucose levels in CD-fed and HFD-fed Rptorob
−/− mice
were significantly lower than the control mice fed a matching
diet (Figure 2B). In HFD-fed Rptorob
−/− mice, this was accompa-
nied by significantly lower fasting insulin levels (Figure 2C). Cal-
culation of the homeostatic model assessment of insulin
resistance (HOMA-IR) identified Rptorob
−/− mice as being more
insulin-sensitive than HFD-fed control mice (Figure 2D). Consis-
tent with this, ITT revealed a higher responsiveness to insulin in
Rptorob
−/− mice compared to the controls, irrespective of diet
(Figure 2E,F). Importantly, although no difference in glucose tol-
erance was observed in the CD-fed Rptorob
−/−mice compared to
the CD-fed controls (consistent with CD-fed Rptorob
−/− mice at
8 weeks; Figure 1S), HFD-fed Rptorob
−/− mice were protected
from developing glucose intolerance as evidenced by significant
lower incremental area under the curve calculation (iAUC) com-
pared to HFD-fed control mice (Figure 2G,H). Collectively, these
results suggest that suppression of OB-mTORC1 protects female
mice from developing diet-induced systemic impairment of glu-
cose metabolism.
Female Rptorob
−/− mice are resistant to an HFD-induced
increase in fat mass
Analysis of body weight over time revealed diet-specific and
genotype-specific differences in weight gain. After 12 weeks on
the HFD, control (Ctrl) mice weighed significantly more and
showed substantial weight gain relative to CD-fed controls
(17.26  1.02 g in HFD-Ctrl vs. 11.21  1.01 g in CD-Ctrl:
Figure 3A–D). Conversely, Rptorob
−/− mice gained the same
amount of weight on both diets (12.05  0.44 g in HFD-
Rptorob
−/− vs. 10.80  0.79 g in CD-Rptorob−/−; Figure 3B,C).
Notably, analysis of weekly weight gain showed that, although
HFD-fed Rptorob
−/− mice initially gained weight more rapidly,
compared to HFD-fed controls, weight gain in the Rptorob
−/−
mice plateaued after approximately 6 weeks (Figure 3C,D). Thus,
Rptorob
−/−mice gained only a small amount of additional weight
thereafter (i.e., from 6 to 13 weeks on HFD, control mice gained
7.2 g, whereas Rptorob
−/−mice gained only 1.7 g; Figure 3D). Fur-
ther examination of end-point body composition revealed that
HFD-fed control mice mainly gained fat (with no difference in
lean mass observed between CD-fed Ctrl and HFD-fed Ctrl,
whereas HFD-fed Rptorob
−/− mice gained both fat and lean mass
relative to CD-fed Rptorob
−/−mice (Figure 3E and F, respectively).
Consistent with this, the percentage of fat mass, relative to body
weight, was significantly higher in control mice relative to
Fig. 2. Female HFD-fed Rptorob
−/−mice are protected against diet-induced impairment of glucosemetabolism. (A) Wild-typemice were fed an HFD or CD
for 12 weeks and steady-state phosphorylation levels of rpS6 and AKT in indicated tissues were measured by Western blotting. (B) Fasting blood glucose
levels in 16-week-old (n = 8–14/genotype). (C) Fasting serum insulin levels at 16 weeks of age (n = 8/genotype). (D) HOMA-IR calculation for 16-week old
HFD-fed mice (n = 8/genotype). (E) Insulin tolerance test and (F) area under the curve analysis at 16 weeks of age (n = 6–15/group). (G) Glucose tolerance
test and (H) incremental area under the curve analysis (n = 8–15/genotype). All panels except A, E, and G: Data are presented as box-plot with mean, max-
imum, and minimum values. *p < 0.05, **p < 0.01, ***p < 0.001, two-way ANOVA with Tukey’s post hoc test. For panel E and G: Data are expressed as
mean  SEM. ap < 0.05 between CD-fed Ctrl and CD-fed Rptorob−/−, bp < 0.05 between HFD-fed Ctrl and HFD-fed Rptorob−/−and cp < 0.05 between CD-
fed Ctrl and HFD-fed Ctrl, two-way ANOVA with Tukey’s post hoc test. Abbreviations: AKT, protein kinase B; ANOVA, analysis of variance; CD, control diet;
Ctrl, control; HFD, high-fat diet; HOMA-IR, homeostatic model assessment of insulin resistance; rpS6, ribosomal protein S6; SEM, standard error of
the mean.
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Rptorob
−/− mice on both diets (Figure 3G). Furthermore, analysis
of inguinal and gonadal fat depots revealed significantly lower
body weight–adjusted fat mass in the HFD-fed Rptorob
−/− mice
compared to the HFD-fed control mice (Figure 3H,I).
Female Rptorob
−/− mice display increased expression of
UCP1 in the inguinal fat despite no significant changes in
total energy expenditure
To examine the underlying mechanisms responsible for the altered
body composition of Rptorob
−/− mice, serum leptin levels, food
intake, energy expenditure, and physical activity were examined.
To account for the differences in their body size, each of these
metabolic parameters was normalized to leanmass. In keepingwith
an increase in fat mass (Figure 3E), circulating leptin levels were
found to be significantly increased in the HFD-fed control mice
(Figure 4A). In contrast, despite a significant increase in %fat mass
in HFD-fed Rptorob
−/− mice relative to CD-fed Rptorob
−/− mice
(Figure 3G), no difference in leptin levels was observed (Figure 4A).
Food consumption, normalized to lean mass, was lower in the CD-
fed Rptorob
−/− mice compared to CD-fed controls (Figure 4B). How-
ever, when fed an HFD, no significant difference in food intake was
observed in Rptorob
−/−mice relative to HFD-fed controls (Figure 4B).
The obesity-resistant phenotype of Rptorob
−/− mice was also inde-
pendent of changes in total energy expenditure, oxygen consump-
tion, respiratory quotient, or physical activity (Figure 4C–F). Of note,
Fig. 3. Female HFD-fed Rptorob
−/−mice are protected against diet-induced obesity and total fat gain. (A) Representative DXA images of 16-week-oldmice. Scale
bar = 2 cm. (B) Temporal body weight changes (n = 6–15/genotype). (C) Temporal and (D) end-of-study (16 weeks old) body weight gain in response to CD or
HFD (n=6–15/genotype). (E–G) DXAanalysis of total fat and leanmass and% fatmass normalized to total bodyweight (n=6–9/genotype). (H–I) iWAT andgWAT
fat pad mass, normalized to body weight (n = 6–9/genotype). All panels except A: Data are presented as box-plot with mean, maximum, and minimum values.
**p < 0.01, ***p < 0.001, two-way ANOVA with Tukey’s post hoc test. Abbreviations: ANOVA, analysis of variance; CD, control diet; DXA, dual-energy absorpti-
ometry; gWAT, gonadal white adipose tissue; HFD, high-fat diet; iWAT, inguinal white adipose tissue.
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a significant reduction in physical activity was observed in the CD-
fed Rptorob
−/− mice compared to the controls (Figure 4H). Interest-
ingly, analysis of energy balance (i.e., energy intake minus energy
expenditure) revealed a negative energy balance in CD-fed
Rptorob
−/−mice and a positive energy balance in HFD-fed Rptorob
−/−
mice (Figure 4G).
Previous studies have shown that a positive energy balance can
induceuncoupledthermogenesis.(39–41)To investigatethisquestion,
weexaminedexpressionofPcg1α andUcp1mRNAs in the interscap-
ular brown adipose tissue (iBAT) of these mice. The mRNA levels of
both Pcg1α and Ucp1were significantly upregulated in response to
HFD; however, there was no significant difference between
Fig. 4. FemaleHFD-fedRptorob
−/−miceexhibitupregulatedUCP1expressiondespiteunchangeddaily foodintake,oxygenconsumption,andenergyexpenditure.
(A) Serumleptin levels inHFD-fedmiceat16 weeksofage (n=6–8/genotype). (B)Daily food intakenormalized to leanmass (kcal/g leanmass) inCD-fedorHFD-fed
mice(n=7–9/genotype). (C) Energyexpenditure,normalizedto leanmass, (n=7–9/genotype). (D)Volumeofoxygenconsumptionnormalizedto leanmass, (n=7–
9/genotype). (E) Average respiratory quotient (n=7–9/genotype). (F) Total activitymeasuredasdistanceofmovement (n=7–9/genotype). (G) Energybalance cal-
culatedasenergyexpenditure-energy intake (n=7–9/genotype).Geneexpression levelsofBATmarkers inCD-fedandHFD-fed iBAT (H) and iWAT(I), normalized to
β-actin (n= 5/genotype). (J) Gene expression levels of BATmarkers in HFD-fed iWAT. (K) Levels of UCP1 protein expression in HFD-fed iWAT tissue (top panel) and
quantitativeanalysisofprotein levels relative toβ-actin (bottompanel) (n=5–6/genotype).AllpanelsexceptK (toppanel):Dataarepresentedasbox-plotwithmean,
maximum,andminimumvalues.*p < 0.05,***p < 0.001, two-wayANOVAwithTukey’sposthoc test.Abbreviations:ANOVA, analysisof variance; BAT,brownadi-
pose tissue; CD, control diet; HFD, high-fat diet; iBAT, interscapular brown adipose tissue; iWAT, inguinal white adipose tissue.
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genotypes (Figure4H).However,expression levelsofPgc1aandUcp1
in inguinal white adipose tissue (iWAT) were greatly upregulated in
HFD-fedRptorob
−/−mice (Figure 4I). Furthermore, a strongupregula-
tionof theexpressionof other genes associatedwith thermogenesis
(e.g., Cidea and Cox7a) was observed in HFD-fed Rptorob
−/− iWAT
samples compared toHFD-fed controls (Figure 4J).Western blotting
of protein lysatesmade from iWAT revealed a significant increase in
UCP1 protein levels in HFD-fed Rptorob
−/− mice compared to the
HFD-controls (Figure 4K).
HFD feeding rescues defects in bone of female
Rptorob
−/− mice
Bone mass and skeletal integrity are greatly impacted by obesity
and HFD feeding. Several lines of evidence demonstrate that
increased marrow adiposity is associated with lower BMD and
increased skeletal fragility in HFD-fed rodents(42,43) and obese
or diabetic human patients.(44,45) Importantly, a decrease in the
number of differentiated OBs and diminished quantities of
Table 1. Trabecular and cortical bone properties in 16-week-old female mice fed a CD or HFD
Bone properties CD-Ctrl CD-Rptorob
−/− HFD-Ctrl HFD-Rptorob
−/−
Tibia length (mm) 14.453  0.085 13.360  0.324* 14.720  0.155 13.715  0.314**
Proximal tibia
Trabecular bone
BV/TV(%) 8.386  0.462 7.885  0.559 8.879  0.255 7.271  0.465
Tb.Th (mm) 0.059  0.001 0.056  0.001 0.061  0.001 0.063  0.001***
Tb.N (1/mm) 1.434  0.082 1.399  0.102 1.466  0.034 1.146  0.073**
Tb.Pf (1/mm) 32.262  0.457 30.382  1.103 28.564  1.272* 28.519  0.543
Tb.Sp (mm) 0.439  0.015 0.408  0.026 0.448  0.006 0.461  0.022
Cortical bone
Ct.Th (mm) 0.156  0.006 0.105  0.005* 0.152  0.006 0.125  0.006**,***
Midshaft tibia
Ct.Th (mm) 0.294  0.012 0.248  0.015 0.286  0.017 0.276  0.011
Ma.Dm (mm) 0.793  0.026 0.691  0.026 0.876  0.030 0.837  0.033***
B.Ar (mm2) 0.823  0.034 0.600  0.053* 0.866  0.053 0.800  0.051***
Ma.Ar (mm2) 0.434  0.019 0.326  0.021 0.515  0.032 0.497  0.036***
Total bone area (mm2) 1.256  0.050 0.926  0.072* 1.381  0.083 1.297  0.085***
Note: Data are expressed as mean  SEM from n = 5–7/genotype; two-way ANOVA with Tukey’s post hoc test.
Abbreviations: ANOVA, analysis of variance; B.Ar, bone area; BV/TV, bone volume/total volume; CD, control diet; Ctrl, control; Ct.Th, cortical thickness;
HFD, high-fat diet; Ma.Ar, marrow area; Ma.Dm, marrow diameter; SEM, standard error of the mean; Tb.Pf, trabecular bone pattern factor; Tb.N, trabecular
number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness.
*p < 0.05 versus CD-fed Ctrl group.
**p < 0.05 versus HFD-fed Ctrl group;
***p < 0.05 versus CD-fed Rptorob
−/− group.
Fig. 5. Female HFD-fed Rptorob
−/−mice are protected against HFD-inducedmarrow adipose tissue expansion. (A) Representative H&E–stained sections of
the proximal tibia in CD-fed or HFD-fed mice. Scale bar = 500 μm. (B) Percentage area occupied by adipocytes per marrow area (%Ad.Ar/Ma.Ar). (C) Aver-
age adipocyte size (Ad.Ar/Ad.N). (D) Numbers of adipocytes per marrow area (Ad.N/Ma.Ar). All panels except A: Data are presented as box-plot with mean,
maximum, and minimum values from n = 5/genotype. **p < 0.01, ***p < 0.001, two-way ANOVA with Tukey’s post hoc test. Abbreviations: Ad.Ar, adipo-
cyte area; Ad.N, number of adipocytes; ANOVA, analysis of variance; CD, control diet; H&E, hematoxylin and eosin; HFD, high-fat diet; Ma.Ar, marrow area.
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osteoid, leading to a poorly organized bone structure and
decreased bone quality, and increased fracture risk are often
observed in type 2 diabetic patients.(46–48) To investigate the
effects of diet and loss of OB-mTORC1 function on skeletal devel-
opment, trabecular and cortical bone in the secondary spon-
giosa proximal to the tibial growth plate of the 16-week-old
control and Rptorob
−/− female mice were analyzed. Female
Rptorob
−/− mice were found to have significantly shorter tibias
than the controls, irrespective of diet (Table 1). Despite the signif-
icant anabolic role of mTORC1, no significant difference in BV/TV
was observed in Rptorob
−/− mice, relative to control mice, on
either diet (Table 1) although a trend toward a decrease in BV/
TV (p = 0.09) was observed in the HFD-fed Rptorob
−/− compared
to the HFD-fed controls (Table 1). The effect of HFD on trabecular
bone in the control mice appeared to be minor because only tra-
becular bone pattern factor (Tb.Pf), which indicates levels of con-
nectivity between trabecular structures, was significantly
decreased in the HFD-fed compared to CD-fed controls
(Table 1). Conversely, Tb.Th was significantly increased in the
HFD-fed compared to CD-fed Rptorob
−/− mice (Table 1). A signif-
icant decrease in Tb.N was observed in HFD-fed Rptorob
−/− mice
compared to HFD-fed controls (Table 1). Measurement of Ct.Th,
at the proximal tibia, was significantly reduced in the Rptorob
−/−
mice compared to the controls in both diets (Table 1). However,
analysis of cortical bone at the mid-shaft or diaphysis of the tibia,
which is composed of more inert cortical bone surrounding the
intramedullary cavity, showed no significant changes in Ct.Th
in Rptorob
−/− mice compared to the controls in both diets
(Table 1). Consistent with the proximal trabecular bone, HFD
feeding did not have a substantial impact on midshaft cortical
bone of the control mice (i.e., no significant changes in any
parameters observed). Marrow diameter (Ma.Dm) and area (Ma.
Ar) were significantly higher in the HFD-fed compared to CD-
fed Rptorob
−/− mice (Table 1). These increases in Ma.Dm and
Ma.Ar in the HFD-fed Rptorob
−/− mice were associated with
increase in bone area (B.Ar) and total bone area. Interestingly,
although B.Ar and Ma.Ar showed a significant or a trend toward
significant decrease in the CD-fed Rptorob
−/− mice compared to
CD-fed controls, no significant changes were observed between
genotypes under HFD (Table 1).
Decreased bone marrow adiposity observed in HFD-fed
Rptorob
−/− mice
To evaluate the effect of HFD on bone marrow adiposity, histo-
morphometric analysis of hematoxylin and eosin–stained sec-
tions of bones were performed. In addition to reduced cortical
thickness, significantly higher levels of intramedullary adipo-
cytes (i.e., percentage of area occupied by adipocytes per total
marrow area (proximal tibia adiposity: %Ad.Ar/Ma.Ar), numbers
of adipocytes per marrow area (N.Ad/Ma.Ar) and average adipo-
cyte size (Ad.Ar/N.Ad) were observed in the tibias of CD-fed
Rptorob
−/− mice compared to the CD-fed controls (Figure 5A–
D). Consistent with previous studies,(43,49,50) 12 weeks of HFD
feeding led to a significant increase in proximal tibia adiposity
and larger average adipocyte size in the controls (Figure 5B,C).
However, no significant changes in the number of adipocytes
per area was observed, suggesting that HFD feeding results in
hypertrophy but not hyperplasia of marrow adipocytes
(Figure 5D). Intriguingly, marrow adiposity was significantly
lower in the HFD-fed Rptorob
−/− mice relative to either CD-fed
Rptorob
−/− mice or HFD-fed controls (Figure 5B). This reduced in
adiposity was associated with a significant decrease in both
number and average size of adipocytes per marrow area relative
to CD-fed Rptorob
−/− mice (Figure 5C,D).
Discussion
In this study, we investigated the effects of bone-specific inhibi-
tion of mTORC1 on the skeleton and metabolic parameters in
response to a control or obesogenic HFD in female mice. Dele-
tion of Rptor, an essential component of mTORC1, in pre-OBs
was shown to have a profound effect on skeletal development
in young (8-week-old) mice, as evidenced by a significant reduc-
tion in trabecular bone volume and trabecular number; however,
most of these differences were resolved by 16 weeks of age.
Notably, although 12 weeks of HFD increased marrow adiposity
with minimal changes in both trabecular and cortical bone in
the female control mice, marrow adiposity was significantly
reduced in HFD-fed Rptorob
−/− compared to both HFD-fed con-
trol and CD-fed Rptorob
−/− mice. Furthermore, Rptorob
−/− mice
were resistant to HFD-induced weight gain and protected from
the development of diet-induced insulin resistance.
Bone phenotypes
Previous studies from our laboratory and others have shown that
mTORC1 plays an important role in bone formation and OB dif-
ferentiation, with conditional inactivation of OB-mTORC1 result-
ing in severe osteopenia and increased skeletal fragility in male
mice.(31,51,52) In the current study, it was found that at 8 weeks
of age, female Rptorob
−/− mice not only exhibit a low bone mass
phenotype (i.e., significantly reduced %BV/TV, decreased Tb.N in
proximal tibia and reduced Ct.Th), but also display a marked
whole-body metabolic phenotype characterized by low glyce-
mic levels, and increased insulin sensitivity. These findings are
consistent with our previous observations in the male Rptorob
−/−
mice(27,31) (A comparison of phenotypes observed betweenmale
and female Rptorob
−/−mice is summarized in Table 2). Unexpect-
edly, however, the trabecular bone defects observed in 8-week-
old CD-fed female Rptorob
−/− mice were almost completely
resolved by 16 weeks of age, although the reduction in cortical
bone thickness persisted. This “normalization” of the trabecular
bone defects could indicate an initial delay in trabecular bone
formation in young Rptorob
−/− mice that is resolved over time.
Alternatively, female Rptorob
−/− mice are protected from further
age-related bone loss such that the age-induced decrease in tra-
becular BV/TV observed in the control mice reduced the magni-
tude of differences between control and Rptorob
−/− mice. In
support of this, studies have reported that, on standard chow
diet, wild-type females lose more bone and strength as they
age,(53) whereas bone structure and function were preserved in
the chow-fed wild-type males up to 18 months of age.(54)
In response to HFD feeding, we observed little or no significant
changes in both trabecular and cortical bone parameters in the con-
trol mice. This was consistent with some(43,55) but not other stud-
ies.(49,50,56–60) Studies using C57BL/6J male mice fed with HFD
from 4 to 23 weeks of age,(56) 12 to 23 weeks of age,(57) or 7 to
28 weeks of age(58) have reportedpositive correlation betweenobe-
sity and BMD, associated with higher femoral Tb.Th and mineral
content and higher cortical bone area and thickness despite lower
bone formation and highmarrow adiposity. Conversely, other stud-
ies stated deleterious effects in the distal femur and proximal tibia
including lower trabecular BV/TV, increased bone turnover, and
higher receptor activator of nuclear factor kappa B ligand (RANKL),
tumor necrosis factor (TNF), and peroxisome proliferator–activated
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receptor (PPAR)-gamma along with higher marrow adiposity and
lower fracture resistance.(49,50,59,60) We speculate that the disparity
between our female control mice and those from other studies
could stem from the differences in animal strains, diet composition,
and duration of HFD.
In contrast, for Rptorob
−/−mice, HFD feeding resulted in signif-
icantly higher trabecular and cortical bone thickness (although
trabecular number showed a trend toward reduction) in the
proximal tibia compared to the CD-fed mice. A previous study
reported a correlation between trabecular thickness and sys-
temic glycemic levels.(61) Therefore, it is possible that some of
the bone phenotypes, observed in the HFD-fed Rptorob
−/− mice,
are due, in part, to the protective metabolic phenotypes of delet-
ing Rptor in bone (i.e., maintain normal glucose homeostasis and
resistance to HFD-induced weight gain).
Inactivation of OB-specific nutrient sensing mTORC1
results in dietary restriction–like phenotypes
At 16 weeks of age, bone marrow adipose tissue (BMAT) was sig-
nificantly elevated in the CD-fed Rptorob
−/− mice compared to
the CD-fed controls and conversely, BMAT was significantly
reduced in HFD-fed Rptorob
−/− mice compared to both CD-fed
Rptorob
−/− and HFD-fed controls. These results were somewhat
unexpected, given the consistent association between HFD feed-
ing and enhanced marrow adiposity reported in previous animal
studies.(43,49,50,57,60,62) It is interesting to note that, unlike male
Rptorob
−/− mice, elevated BMAT was not observed in 4-week-
old female Rptorob
−/− mice (i.e., the age at which mice were
assigned to either CD or HFD; Supplementary Figure S1). This
suggests that the BMAT accumulation observed in the
16-week-old CD-fed but not in HFD-fed Rptorob
−/− mice is likely
due to other factors (e.g., diet, metabolic hormones, or systemic
energy status) and not the expansion or lipolysis of preexisting
bone marrow adipocytes (BMAds).
Intriguingly, the significant expansion of BMAds in the CD-fed
female Rptorob
−/−mice coincidedwith a calorie-deficient state, in
that their energy intake was substantially lower than their energy
expenditure (Figure 4G). Expansion of BMAds has been reported
in response to changes in nutrient availability including starva-
tion (reviewed in Devlin(63)), leptin deficiency,(64) dietary restric-
tion (DR),(65) and HFD feeding(43,49) in mice, and also in human
Table 2. Summary of phenotypes associated with loss of mTORC1 function in preosteoblasts in male and female Rptorob
−/− mice fed
normal chow and HFD
CD-fed HFD-fed, 16 weeks
Phenotype Female, 8 weeks old Male, 4 and 12 weeks old Female Male
Weight gain Constant after 6 weeks on HFD
Body weight # # # #
% Fat $ # # #
% Lean $ " " "
BMD (g/cm2) # # $ #
BV/TV (%) # # $ n/a
Tb.N (1/mm) # # # n/a
Tb.Th (mm) $ # $ n/a
Ct.Th (mm) # # $ n/a
iWAT (g/g BW) # $ # #
gWAT (g/g BW) # # # #
BAT (g/g BW) $ $ # $
EE (kcal/g lean mass) $ " $ " dark
Food intake (g/g BW) # $ $ $
RQ $ # # light" dark # light " dark
%Fecal lipid $ $ $ $
Browning of WAT n/a n/a " "
Metabolic phenotype
Fasting glucose # # # #
Insulin sensitivity " " " "
Glucose tolerance $ " " "
GSIS " " " "
Serum analysis
Fasting insulin # # # #
Leptin # # # #
Adiponectin " " " "
Total OCN # # # $
unOCN # # $ $
Note: CD-fed 4-week-old and 12-week-old Rptorob
−/− mice(31) and HFD-fed 16-week-old Rptorob
−/− mice.(27)
Abbreviations: ", increased; #, decreased;$, unchanged relative to control group for each sex and diet; BAT, brown adipose tissue; BMD, bone mineral
density; BV/TV, bone volume/total volume; BW, body weight; CD, control diet; Ct.Th, cortical thickness; EE, energy expenditure; GSIS, glucose-stimulated
insulin secretion; gWAT, gonadal white adipose tissue; HFD, high-fat diet; iWAT, inguinal white adipose tissue; mTORC1, mammalian target of rapamycin
complex 1; n/a, data not available; OCN, osteocalcin; RQ, respiratory quotient; Tb.N, trabecular number; Tb.Th, trabecular thickness; unOCN, undercarboxy-
lated osteocalcin; WAT, white adipose tissue.
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with anorexia nervosa patients.(66) BMAT expansion, under
restricted dietary conditions, was shown to be responsible for
elevated circulating adiponectin levels that promote systemic
improvements in glucose metabolism(66–68) and, as such, ele-
vated serum adiponectin levels could contribute to the
improved metabolic phenotype of Rptorob
−/− mice. DR has been
shown to extend lifespan in several organisms(69) and reduce or
delay the development of age-related diseases such as cardiovascu-
lar disease, cancer, metabolic diseases, and muscle atrophy.(70–72)
During DR, low nutrient and high AMP/ATP ratios activate AMPK,
which inhibits mTORC1 by activating TSC2,(12) a negative regulator
of mTORC1, and/or by phosphorylating RAPTOR.(13) Consistent with
this view, pharmaceutical inhibition of TOR signaling (via rapamycin
treatment) extends lifespan(17,73,74) and genetic ablation of S6K1 in
mice (S6K1−/−) leads to a gene expression profile similar to that of
DR mice. Of note, female S6K1−/− mice are long-lived and have a
reduced incidence of age-related diseases.(20) Concordance in the
phenotypes of calorie-restricted mice and Rptorob
−/− mice
(i.e., hypoleptinemia, hypoinsulinemia, high corticosterone, and an
increase in ketone bodies) suggests that loss of mTORC1 function
in OBs mimics a starvation response. Furthermore, a reduction in
bonemass and an expansion of BMAT in the female Rptorob
−/−mice
combinedwith elevated circulating adiponectin levels, as evident in
this study, suggest that suppression ofmTORC1 function inOBs trig-
gers a “starvation response” in the bone which leads to starvation-
induced BMAT formation and physiological adaptation to
starvation.
Sex-dimorphism effects of OB mTORC1 inactivation
In contrast to CD-fed male Rptorob
−/− mice,(27) an improvement
in glucose tolerance and reduction in % fat mass were not
observed in female CD-fed Rptorob
−/− mice (Table 2). We specu-
late that thismay be attributable to sex asymmetry and the effect
of sex hormones on metabolism (reviewed in Mauvais-Jarvis(75)).
Females resist the loss of energy stores better than males, which
may also contribute to the sex-specific differences observed in
Rptorob
−/− mice. Indeed, sex-specific differences in the ability to
resist loss of fat storage are known to occur in other stains of
mice.(76,77) In female CD-fed Rptorob
−/− mice, their unaltered
energy expenditure, despite a lower food intake (either absolute
or adjusted to their body size), suggests that they are in a caloric
deficit. Recent evidence suggests skeletally-derived lipocalin
(LCN2) can suppress food intake(78); however, we found no
changes in circulating LCN2 levels in female Rptorob
−/− mice
compared to controls (data not shown). In contrast, circulating
leptin levels were significantly decreased in female CD-fed
Rptorob
−/− mice, despite their lower food intake. We postulate
that the hypoleptinemia observed in Rptorob
−/− mice is a conse-
quence of their low adiposity and negative energy balance (due
to their lower dietary intake); however, further studies are
required to determine if other appetite-regulating hormones
(i.e., ghrelin, neuropeptide Y, peptide YY, and other gut hor-
mones) could be playing a role.
In recent years, the effects of mTORC1 perturbation have been
examined in several different metabolic tissues including WAT,
skeletal muscle, and liver, with each revealing a distinctive role
for mTORC1 signaling in the tissue itself, and on global metabo-
lism as a whole. For example, HFD-fed mice with hepatic knock-
down of S6K1/2 have improved systemic insulin sensitivity and
glucose tolerance, and are protected against hepatic steato-
sis.(79) In contrast, mice with deletion of Rptor in WAT suffer from
severe hepatic steatosis despite being protected against diet-
induced obesity (via increased energy expenditure).(80,81) Simi-
larly, inactivation of mTORC1 in skeletal muscle causes resistance
to HFD-induced metabolic dysfunction and improved glucose
tolerance but has no effect on insulin sensitivity.(82) Furthermore,
systemic inhibition of mTORC1 signaling by rapamycin adminis-
tration(83) or deletion of S6K1(19) results in mice that are resistant
to weight gain due to elevated lipolysis andmetabolic rate. Inter-
estingly, despite the reported mechanistic differences between
these models, one phenotype that is shared among these sys-
temic and tissue-specific mTORC1 knockout (KO) models is that
they are resistant to HFD-induced weight gain. In the current
study, suppression of mTORC1 in OBs was also associated with
resistance to HFD-induced weight gain, consistent with previous
mTORC1 KO models. Although the mechanism underlying
obesity-resistant phenotype of HFD-fed Rptorob
−/−mice requires
further investigation, themechanism is likely to involve the upre-
gulation of Ucp1 expression in the WAT depots of Rptorob
−/−
mice. Similar to our previous findings in male mice,(27) upregula-
tion of UCP1 in WAT was independent of previously reported
browning agents including FGF21,(84) irisin,(85) sclerostin,(86)
and BMP7(87) (Supplementary Figure S2). It is also interesting to
note that the upregulation of UCP1 in Rptorob
−/− mice appears
to be depot-specific, with a marked induction only observed in
the iWAT, whereas upregulation of Ucp1mRNA, but not protein,
was observed in gonadal WAT (gWAT). Furthermore, even
though BMAT in the proximal tibial (which are juxtaposed to tra-
becular bone) has been reported to express markers of brown
fat,(88,89) we were unable to detect Ucp1 transcripts in the bone
of Rptorob
−/− mice (data not shown). Collectively, these results
suggest that the mechanism(s) underlying this increased brow-
ning of white fat in Rptorob
−/− mice could be due to systemic
metabolic alterations or potentially occur in an endocrine, not
paracrine, manner. Further studies interrogating RNA sequenc-
ing data to identify translated genes that encode secreted pro-
teins and nontargeted metabolomic profiling of serum,(90)
involving the use of nuclearmagnetic resonancemass spectrom-
etry or complementary technologies, would be helpful to iden-
tify novel factor(s) responsible for the metabolic phenotype of
Rptorob
−/− mice.
One potential limitation of this study is the use of wild-type lit-
termates as the control group. Several previous studies have
reported Osterix promoter activity(91,92) and Cre recombinase
activity (in tTA:osx:cre mice(93)), in tissues other than bone. These
observations, in addition to the well-documented skeletal phe-
notype of tTA:Osx:cre mice(94–96) has raised doubts as to the
use of wild-type mice as controls. To mitigate this issue, in our
previous publication we compared the metabolic phenotype of
both male and female tTA:Osx:cre mice with age- and sex-
matched wild-type littermates. No differences in fasting glucose
levels, glucose tolerance, insulin sensitivity, and serum osteocal-
cin (total and undercarboxylated) levels were observed.(27) In
regard to the potential influence of the tTA:Osx:cre transgene
on bone biology and glucose homeostasis, most differences
between wild-type and tTA:Osx:cre mice are evident in early
postnatal mice; that is, less than 6 weeks of age,(94–96) and their
bone mass (both cortical and trabecular) normalizes between
6 and 12 weeks of age.(96) Because our studies were performed
at 8 and 16 weeks of age, we believe that the influence of the
tTA:Osx:cre transgene in bone, and hence glucose homeostasis,
will be negligible.
Lineage tracing studies in tTA:Osx:cre mice have also revealed
potential transgene expression in bone marrow adipocytes(93,97)
suggesting altered mTORC1 signaling in BMAT may contribute to
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themetabolic phenotype of Rptorob
−/−mice. Indeed, evidence from
other studies suggests mTORC1 plays an important role in adipose
tissue in the control of glucose homeostasis.(80,81) However, no Cre
activity in the peripheral adipose tissue was reported in any of the
lineage tracing studies using tTA:Osx:cre mice and thus any
adipose-specific contribution to the metabolic phenotype of
Rptorob
−/− mice is limited to BMAT. It should be noted that an
improvement in glucose disposal and insulin sensitivity in female
HFD-fed Rptorob
−/− mice (Figure 5) occurred without an increase
in BMAT. Further investigation is required to determine the role of
mTORC1 in BMAT in glucose homeostasis and how this potentially
contributes to the metabolic phenotype of Rptorob
−/− mice.
In summary, inactivation of bone-specific mTORC1 in female
mice lead to low bone mass at younger ages, which was attenu-
ated by 16 weeks of age. Importantly, these mice are protected
from HFD-induced marrow adiposity expansion, obesity, and
insulin resistance, suggesting an important role for the mTORC1
pathway in the skeletal regulation of glucose metabolism, and
providing strong evidence to support the concept that dysregu-
lated insulin signaling in OBs has systemic effects on glucoregu-
lation and energy homeostasis. These studies highlight the
beneficial systemic consequences of reducing mTORC1 function
in OBs, under nutrient excess, revealing skeletal mTORC1 as a
potential target for anti-obesity and diabetes drugs.
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